Drug profile

The FDA adverse-event record for Vitamin K1

80 FDA reports name Vitamin K1, a high-volume drug in the CVM extract. Species, reactions, and outcomes follow.

#877 of 2,679
by report volume (all drugs)
80
adverse-event reports
60.0%
death-coded share
Dog
most-reported species

Corpus placement

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Vitamin K1 ranks #871 of 2679 by total reports (80) and #45 of 1130 by death-coded share (60.0%). National dual: Milbemycin Oxime + Spinosad is #1 of 2679 drugs by total adverse-event reports (149,624) at death-coded-share rank 965 of 1130 drugs with at least 50 reports (2.3%); separately, Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) is #1 highest death-coded share at 97.8% (report rank #821).

149,624
Milbemycin Oxime + Spinosad reports (#1)
97.8%
Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) death share (#1)
#871
This drug, reports of 2679
#45
This drug, death share of 1130

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Vitamin K1 has 80 reports now versus 80 in that prior snapshot: 0 the same number of (0.0%).

Report change
+0
Death-coded reports
+0
Death-coded share
+0.0 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Vitamin K1 changes

Signature read: Vitamin K1's 60.0% death-coded share is among the highest in the openFDA drug corpus.

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
80
Total Reports
48
Deaths Reported
60.0%
Death-coded share of reports

Active Ingredients

Vitamin K1

Administration Routes

UnknownOralSubcutaneous

Species Affected

Dog 70
Cat 10

Most Affected Breeds

Retriever - Labrador 20
Domestic Shorthair 8
Terrier - Bull - American Pit 3
Crossbred Canine/dog 3
Boxer (German Boxer) 3
Maltese 2
Griffon - Brussels 2
Mixed (Dog) 2
Domestic Longhair 2
Shepherd (unspecified) 2

Most Reported Reactions

Vomiting 42
Lethargy (see also Central nervous system depression in 'Neurological') 37
Other abnormal test result NOS 34
Elevated total bilirubin 30
Death by euthanasia 30
Elevated alanine aminotransferase (ALT) 29
Anaemia NOS 28
Thrombocytopenia 28
Anorexia 23
Elevated serum alkaline phosphatase (SAP) 23
Leucocytosis NOS 21
Elevated liver enzymes 21

Outcome Breakdown

Euthanized
30 (37.5%)
Ongoing
26 (32.5%)
Died
18 (22.5%)
Recovered/Normal
6 (7.5%)

Vitamin K1: high death-coded share in the FDA AER row

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

High-volume nationwide drug peers

Two openFDA-derived peer sets for Vitamin K1, both floored at ≥50 reports so the neighborhoods stay in the advertised mass.

Similar death-coded share

Nearest other drugs by death-coded share (60.0% here), distinct from the volume row.

What to do with this drug

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Vitamin K1 (#877 of 2,679 by report volume); death-coded 60.0%. PlainBreed drug row · death-coded share stamp 60.0% · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →